Can ipamorelin increase testosterone levels in women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Ipamorelin Increase Testosterone Levels in Women?

No, ipamorelin does not increase testosterone levels in women. Ipamorelin is a selective growth hormone secretagogue that specifically stimulates growth hormone (GH) release without affecting other pituitary hormones, including those that regulate testosterone production.

Mechanism of Action and Hormonal Specificity

  • Ipamorelin is a pentapeptide that selectively stimulates GH release through GHRP-like receptors in the pituitary gland, with potency and efficacy comparable to other growth hormone-releasing peptides 1
  • Critically, ipamorelin demonstrates remarkable selectivity—it does not affect FSH, LH, prolactin, TSH, ACTH, or cortisol levels, even at doses more than 200-fold higher than the effective dose for GH release 1
  • This hormonal specificity distinguishes ipamorelin from other growth hormone secretagogues like GHRP-6 and GHRP-2, which can elevate ACTH and cortisol 1

Why Testosterone Is Not Affected

  • Testosterone production in women occurs primarily in the ovaries and adrenal glands, regulated by LH and ACTH respectively 2
  • Since ipamorelin does not stimulate LH or ACTH secretion, it cannot trigger the hormonal cascade necessary for testosterone synthesis 1
  • The drug's mechanism is confined to GH release through specific GHRP receptors, with no cross-reactivity with gonadotropin or adrenal pathways 1

Evidence from Animal Studies

  • In young female rats treated chronically with ipamorelin for 21 days, the compound increased GH content in somatotroph cells and enhanced GH secretion, but no effects on sex hormones were reported 3
  • Studies in adult female rats receiving ipamorelin for 15 days showed dose-dependent increases in longitudinal bone growth and body weight, but total IGF-I levels remained unchanged, and no sex hormone measurements were altered 4
  • A 3-month study in 8-month-old female rats demonstrated that ipamorelin increased muscle strength and bone formation without any reported effects on reproductive hormones 5

Clinical Implications for Women

  • If a woman seeks to increase testosterone levels, ipamorelin is not an appropriate intervention 1
  • Testosterone therapy itself in women is challenging because high doses inevitably cause virilization (facial hair, voice deepening, clitoral enlargement), making it difficult to achieve muscle-building effects without masculinizing side effects 2, 6
  • Women with true hypogonadism and low testosterone may benefit from testosterone replacement at 150 mg/day, though evidence shows only modest improvements in muscle mass and strength without significant weight gain 2

Common Pitfalls to Avoid

  • Do not confuse GH stimulation with testosterone stimulation—these are entirely separate hormonal pathways with different regulatory mechanisms 1
  • Do not assume that increased muscle mass from GH secretagogues implies increased testosterone—GH can promote anabolic effects through IGF-I pathways independent of androgens 4, 5
  • Do not use ipamorelin off-label for testosterone enhancement in women—there is zero mechanistic basis or clinical evidence for this indication 1

Alternative Approaches for Women Seeking Hormonal Optimization

  • For women with documented hypogonadism (low testosterone with symptoms), testosterone replacement therapy is the evidence-based approach, though benefits are modest and virilization risk is high 2
  • For women with functional hyperprolactinemia causing reproductive dysfunction, addressing the underlying cause (epilepsy treatment, stress reduction) may normalize sex hormone levels 2
  • Weight loss and metabolic optimization can improve endogenous testosterone production in women with obesity-associated hormonal dysfunction, similar to effects seen in men 7

In summary, ipamorelin's highly selective mechanism of action on GH release, with no effect on LH, FSH, or ACTH, makes it physiologically incapable of increasing testosterone levels in women. 1

References

Research

Ipamorelin, the first selective growth hormone secretagogue.

European journal of endocrinology, 1998

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 1999

Research

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001

Guideline

Biological Sex Differences in Muscle Mass and Testosterone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Testosterone Injection Treatment for Male Hypogonadism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the lowest risk dosing regimen for ipamorelin (growth hormone secretagogue) in adults and its use in teenagers?
What is the lowest dosage of ipamorelin (growth hormone secretagogue) for a teenager to minimize risk?
What are the benefits and dosing recommendations for Ipamorelin (growth hormone secretagogue)?
What is the clinical usage of ipamorelin (growth hormone secretagogue) in practice?
What are the usage guidelines and precautions for ipamorelin (growth hormone secretagogue) therapy?
What is the differential diagnosis and urgent management for a patient presenting with leukopenia (white‑blood cell count 3.1 ×10⁹/L), red‑blood cell count 2.25 ×10¹²/L, severe macrocytic anemia (hemoglobin 7.6 g/dL, hematocrit 23.9 %, mean corpuscular volume 106 fL) and thrombocytopenia (platelet count 80 ×10⁹/L)?
Does codeine cause tachycardia, particularly in patients with pre‑existing cardiac disease, hypertension, or concomitant sympathomimetic medications?
What are the current Ghana tuberculosis (TB) management guidelines, including the recommended first‑line regimen for newly diagnosed drug‑susceptible cases, the Category II regimen for retreatment cases, dosing for children and pregnant women, HIV co‑treatment recommendations, and the approach to multidrug‑resistant (MDR) TB?
What peri‑operative antibiotic regimen is recommended for an adult with acute appendicitis and no known drug allergies?
In a patient currently receiving dexamethasone (Decadron) with a morning serum cortisol of 2.6 µg/dL, does this indicate adrenal insufficiency and how should adrenal reserve be evaluated?
What is the optimal secondary prevention regimen for a patient who has suffered a lacunar infarct?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.